Multiple Sclerosis, Relapsing-Remitting: all 615 studies

Page 5 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.

• Clinical Disease Activity With Long Term Natalizumab TreatmentCompletedNCT02677077
• Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MSWithdrawnNCT02675413Phase 4
• Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient SatisfactionCompletedNCT02652091
• A Pilot Study of Intermittent Calorie Restriction in Multiple SclerosisCompletedNCT02647502Not applicable
• This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 YearsCompletedNCT02638038Phase 2
• Observational Registry of Acthar Gel for Participants With Multiple Sclerosis RelapseCompletedNCT02633033
• Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis ConditionCompletedNCT02598167
• Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?CompletedNCT02588053
• A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSStatus unknownNCT02587806Phase 1/2
• A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSStatus unknownNCT02587715Phase 1/2
• Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple SclerosisTerminatedNCT02580669Not applicable
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012CompletedNCT02579681Phase 3
• Brimonidine Tartrate for the Treatment of Injection Related ErythemaWithdrawnNCT02568111Phase 4
• Mitochondrial Dysfunction and Disease ProgressionCompletedNCT02549703
• Phase I BP Interferon (IFN) Beta-004CompletedNCT02517788Phase 1
• Phase I BP Interferon (IFN) Beta-001CompletedNCT02515695Phase 1
• Open-label Study of Liothyronine in MSCompletedNCT02506751Phase 1
• Autologous Mesenchymal Stromal Cells for Multiple SclerosisCompletedNCT02495766Phase 1/2
• Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT02493049Phase 2
• Teriflunomide Observational Effectiveness StudyCompletedNCT02490982
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple SclerosisWithdrawnNCT02472938Phase 4
• Tecfidera and the Gut MicrobiotaCompletedNCT02471560Phase 4
• Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple SclerosisCompletedNCT02461069Phase 4
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple SclerosisTerminatedNCT02427776Phase 1/2
• Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple SclerosisCompletedNCT02424396Phase 2
• Oral Guanabenz for Multiple SclerosisTerminatedNCT02423083Phase 1
• Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialCompletedNCT02419378Phase 4
• A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSTerminatedNCT02418325Phase 1/2
• Rotating Frame Relaxation Imaging in Patients With Multiple SclerosisCompletedNCT02403570
• An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
• Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)TerminatedNCT02394782
• Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple SclerosisStatus unknownNCT02369926Phase 2
• Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple SclerosisStatus unknownNCT02364986Phase 1
• PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking FingolimodCompletedNCT02335892
• Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaStatus unknownNCT02325440Phase 4
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)TerminatedNCT02323269
• Comparative Oral Bioavailability Study of MT-1303CompletedNCT02310048Phase 1
• Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple SclerosisCompletedNCT02308670
• Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839TerminatedNCT02306811Phase 2
• Imaging of Intracerebral Inflammation in MSCompletedNCT02305264Not applicable
• Mass Balance Study of MT-1303CompletedNCT02293967Phase 1
• Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)CompletedNCT02280876Phase 1/2
• Disease Control in RRMS Transferring Treatment From Natalizumab to FingolimodCompletedNCT02277964
• Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple SclerosisCompletedNCT02275741
• Improving Cognitive Aptitudes With tDCS in Patients With Multiple SclerosisTerminatedNCT02266121Not applicable
• BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With BetaferonCompletedNCT02247310
• Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple SclerosisTerminatedNCT02222948Phase 2
• Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMSCompletedNCT02212886Phase 1/2
• Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADACompletedNCT02205489Phase 4
• A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303CompletedNCT02193217Phase 1
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)CompletedNCT02159573
• Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
• Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple SclerosisStatus unknownNCT02104492Not applicable
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateWithdrawnNCT02090348Phase 4
• Tolerability and Quality of Life Study in Participants Who Switched to Avonex PenCompletedNCT02076841
• Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisCompletedNCT02035514Phase 1/2
• Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MSCompletedNCT02010554Not applicable
• A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)WithdrawnNCT01975298Phase 3
• Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover DesignCompletedNCT01945359
• Ireland Natalizumab (TYSABRI) Observational ProgramCompletedNCT01943526
• Safety and Efficacy of Fingolimod in MS Patients in ChinaWithdrawnNCT01941004Phase 3
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesCompletedNCT01930708Phase 4
• Development of a Motivational Intervention to Improve Treatment Adherence in MSCompletedNCT01925690Not applicable
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• Extension Study of MT-1303CompletedNCT01890655Phase 2
• PK and PD Study of Natalizumab in Pediatric Subjects With RRMSCompletedNCT01884935Phase 1
• Efficacy of Fish Oil in Multiple SclerosisCompletedNCT01842191Phase 4
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01838668Phase 3
• Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.CompletedNCT01808885Phase 1
• A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT01808482Phase 1
• Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual RealityCompletedNCT01805336Not applicable
• Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With FingolimodTerminatedNCT01790269
• Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple SclerosisCompletedNCT01772199Phase 2
• Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple SclerosisTerminatedNCT01755871Phase 4
• Dose-finding Study of MT-1303CompletedNCT01742052Phase 2
• Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).CompletedNCT01738347Phase 1
• Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01717664Phase 2
• Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnNCT01714089Phase 2
• Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMSWithdrawnNCT01709812Phase 4
• Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsTerminatedNCT01706107
• Impact of Vitamin A on RAR Gene Expression in Multiple SclerosisStatus unknownNCT01705457Phase 4
• Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT01701856Phase 4
• Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) StudyCompletedNCT01628315
• NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessCompletedNCT01591551Phase 4
• Effects of Electromechanical Gait Trainer in Patients With Multiple SclerosisCompletedNCT01564511Not applicable
• A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple SclerosisCompletedNCT01541618
• A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple SclerosisCompletedNCT01538355Not applicable
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
• Worms for Immune Regulation of Multiple SclerosisCompletedNCT01470521Phase 2
• A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.CompletedNCT01466322Phase 1
• Estriol Treatment in Multiple Sclerosis (MS): Effect on CognitionStatus unknownNCT01466114Phase 2
• Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Status unknownNCT01464905Phase 3
• Glatiramer Acetate for Multiple Sclerosis With Autoimmune ComorbiditiesCompletedNCT01456416
• The Effects of Aerobics Training on Balance in Patients With Multiple SclerosisStatus unknownNCT01453868Early Phase 1
• Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)CompletedNCT01450124Phase 2
• Plasma Exchanges in Multiple Sclerosis (MS) RelapsesCompletedNCT01442233Phase 3
• Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisTerminatedNCT01435993Phase 1
• Assessment of Repeat Ascending Doses of GSK2018682 in Healthy VolunteersCompletedNCT01431937Phase 1
• A Phase IIa Study of NT-KO-003 for Multiple SclerosisCompletedNCT01428726Phase 2

← Multiple Sclerosis, Relapsing-Remitting overview